Document is current
Any future updates will be listed below
-
Authors
Jain, Avneesh https://orcid.org/0009-0001-2965-8303
Rørnes, Anna Xiu
Farestveit, Anne
Grinde, Maria Tunset https://orcid.org/0000-0003-4625-2222
Nyman, Axel Karl Gottfrid https://orcid.org/0000-0003-2738-1870
Sitter, Beathe https://orcid.org/0000-0003-1786-6380
Wergeland, Tore https://orcid.org/0000-0003-2295-123X
Tronvik, Erling https://orcid.org/0000-0001-6059-0151
Genovese, Guglielmo https://orcid.org/0000-0001-9409-0120
-
Funding
Funding for this research was provided by:
NTNU Norwegian University of Science and Technology
- License Information
-
More Information
Article History
Received: 22 January 2026
Accepted: 1 July 2026
First Online: 4 July 2026
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK; reference number 253435). All participants received written and oral information about the study and provided written informed consent prior to inclusion.
: Not applicable. All data is presented in anonymized and/or aggregated form, and no identifiable information is included.
: T.W. has received lecture honoraria from TEVA, Roche, LUNDBECK and Lilly, and is a shareholder in two medical device start-up companies (Vilje Bionics AS and Keimon Medical AS). E.T. has received personal fees for lectures/advisory boards: Novartis, Eli Lilly, Abbvie, TEVA, Roche, Lundbeck, Pfizer, Biogen, Organon. Consultant for and owner of stocks and IP in Man & Science. Stocks and IP in Nordic Brain Tech. Stocks in Keimon Medical. Non-personal research grants from several sources, including Norwegian Research Council, KlinBeForsk, EU. Commissioned research (non-personal): Lundbeck. Associate Editor Cephalalgia.
